Q2 2021 Results - Reimagining Medicine
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
CRM
IHD
Neuroscience
Oncology
Ophthalmology
Respiratory
Sandoz Biopharmaceuticals
Global Health
Abbreviations
OMB157 - Anti-CD20
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
NCT03650114 ALITHIOS (COMB157G2399)
Multiple Sclerosis
Phase 3
2010
Evaluate the long-term safety and tolerability of ofatumumab 20 mg subcutaneous
(sc) once every 4 (94) weeks in subjects with RMS from the first dose of
ofatumumab
Ofatumumab 20 mg every 4 weeks
Patients with relapsing MS
Target Patients
Read-out Milesstone(s)
Publication
2028
TBD
90 Investor Relations | Q2 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation